Current trends in the etiology and diagnosis of HPV-related head and neck cancers

Cancer Medicine

Volumn 4, Issue 4, 2015, Pages 596-607

  Chai, Ryan C ^a   Lambie, Duncan ^b   Verma, Mukesh ^c   Punyadeera, Chamindie ^a,d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b IQ PATHOLOGY   (Australia)

^c NATIONAL CANCER INSTITUTE   (United States)

^d QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

HPV; Biomarkers; Epidemiology; Oropharyngeal cancer; Saliva diagnostics

Indexed keywords

IMMUNOGLOBULIN G; ONCOPROTEIN; PROTEIN E6; PROTEIN E7; VIRUS DNA; VIRUS RNA; WART VIRUS VACCINE; CYCLIN DEPENDENT KINASE INHIBITOR 2A;

BODY FLUID; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SCREENING; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MORBIDITY; MOUTH; MOUTH MUCOSA; MOUTH SQUAMOUS CELL CARCINOMA; NON INVASIVE PROCEDURE; OROPHARYNGEAL SQUAMOUS CELL CARCINOMA; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEROLOGY; SQUAMOUS CELL CARCINOMA; TREND STUDY; TUMOR BIOPSY; VACCINATION; VIRUS DETECTION; VIRUS GENE; VIRUS ONCOGENE; VIRUS TYPING; WART VIRUS; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 6; ISOLATION AND PURIFICATION; MALE; METABOLISM; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; SALIVA; VIROLOGY; VIRUS CELL TRANSFORMATION;

CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; CELL TRANSFORMATION, VIRAL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, VIRAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 6; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; ONCOGENE PROTEINS; PAPILLOMAVIRUS INFECTIONS; RNA, VIRAL; SALIVA;

EID: 84984905668     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.424     Document Type: Review

References (100)

1. Ferlay, J., H. R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127:2893-2917.
2. Leemans, C. R., B. J. Braakhuis, and R. H. Brakenhoff 2011. The molecular biology of head and neck cancer. Nat. Rev. Cancer 11:9-22.
3. Jemal, A., F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman 2011. Global cancer statistics. CA Cancer J. Clin. 61:69-90.
4. Sturgis, E. M., and P. M. Cinciripini 2007. Trends in head and neck cancer incidence in relation to smoking prevalence. Cancer 110:1429-1435.
5. Hashibe, M., P. Brennan, S. Benhamou, X. Castellsague, C. Chen, M. P. Curado, et al. 2007. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J. Natl. Cancer Inst. 99:777-789.
6. Pelucchi, C., S. Gallus, W. Garavello, C. Bosetti, and C. La Vecchia 2006. Cancer risk associated with alcohol and tobacco use: focus on upper aero-digestive tract and liver. Alcohol Res. Health 29:193-198.
7. Marur, S., G. D'Souza, W. H. Westra, and A. A. Forastiere 2010. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 11:781-789.
8. Combes, J.-D., and S. Franceschi 2014. Role of human papillomavirus in non-oropharyngeal head and neck cancers. Oral Oncol. 50:370-379.
9. Dahlgren, L., H. Mellin, D. Wangsa, K. Heselmeyer-Haddad, L. Björnestål, J. Lindholm, et al. 2003. Comparative genomic hybridization analysis of tonsillar cancer reveals a different pattern of genomic imbalances in human papillomavirus-positive and-negative tumors. Int. J. Cancer 107:244-249.
10. Benson, E., R. Li, D. Eisele, and C. Fakhry 2013. The clinical impact of HPV tumor status upon head and neck squamous cell carcinomas. Oral Oncol. 50:565-574.
11. Chaturvedi, A. K., E. A. Engels, R. M. Pfeiffer, B. Y. Hernandez, W. Xiao, E. Kim, et al. 2011. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J. Clin. Oncol. 29:4294-4301.
12. Gillison, M. L., G. D'Souza, W. Westra, E. Sugar, W. Xiao, S. Begum, et al. 2008. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J. Natl. Cancer Inst. 100:407-420.
13. Antonsson, A., M. Cornford, S. Perry, M. Davis, M. Dunne, and D. Whiteman 2013. Prevalence and risk factors for oral HPV infection in young Australians. PLoS One 9:e91761.
14. Kurose, K., M. Terai, N. Soedarsono, D. Rabello, Y. Nakajima, R. D. Burk, et al. 2004. Low prevalence of HPV infection and its natural history in normal oral mucosa among volunteers on Miyako Island, Japan. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 98:91-96.
15. Gillison, M. L., T. Broutian, R. K. Pickard, Z.-Y. Tong, W. Xiao, L. Kahle, et al. 2012. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 307:693-703.
16. Du, J., C. Nordfors, A. Ährlund-Richter, M. Sobkowiak, M. Romanitan, A. Näsman, et al. 2012. Prevalence of oral human papillomavirus infection among youth, Sweden. Emerg. Infect. Dis. 18:1468.
17. Plummer, M., M. Schiffman, P. E. Castle, D. Maucort-Boulch, and C. M. Wheeler 2007. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J. Infect. Dis. 195:1582-1589.
18. Kjaer, S. K., A. J. C. van den Brule, G. Paull, E. I. Svare, M. E. Sherman, B. L. Thomsen, et al. 2002. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 325:572.
19. De Martel, C., J. Ferlay, S. Franceschi, J. Vignat, F. Bray, D. Forman, et al. 2012. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 13:607-615.
20. Blomberg, M., A. Nielsen, C. Munk, and S. K. Kjaer 2011. Trends in head and neck cancer incidence in Denmark, 1978-2007: focus on human papillomavirus associated sites. Int. J. Cancer 129:733-741.
21. Hong, A. M., A. E. Grulich, D. Jones, C. S. Lee, S. M. Garland, T. A. Dobbins, et al. 2010. Squamous cell carcinoma of the oropharynx in Australian males induced by human papillomavirus vaccine targets. Vaccine 28:3269-3272.
22. Gillison, M. L., X. Castellsagué, A. Chaturvedi, M. T. Goodman, P. Snijders, M. Tommasino, et al. 2014. Eurogin Roadmap: comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix. Int. J. Cancer 134:497-507.
23. Smith, E. M., J. M. Ritchie, K. F. Summersgill, J. P. Klussmann, J. H. Lee, D. Wang, et al. 2004. Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int. J. Cancer 108:766-772.
24. Hong, A. M., A. Martin, M. Chatfield, D. Jones, M. Zhang, B. Armstrong, et al. 2013. Human papillomavirus, smoking status and outcomes in tonsillar squamous cell carcinoma. Int. J. Cancer 132:2748-2754.
25. Heck, J. E., J. Berthiller, S. Vaccarella, D. M. Winn, E. M. Smith, O. Shan'gina, et al. 2010. Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int. J. Epidemiol. 39:166-181.
26. Dahlstrom, K. R., G. Li, G. Tortolero-Luna, Q. Wei, and E. M. Sturgis 2011. Differences in history of sexual behavior between patients with oropharyngeal squamous cell carcinoma and patients with squamous cell carcinoma at other head and neck sites. Head Neck 33:847-855.
27. Herrero, R., X. Castellsagué, M. Pawlita, J. Lissowska, F. Kee, P. Balaram, et al. 2003. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J. Natl. Cancer Inst. 95:1772-1783.
28. D'Souza, G., A. R. Kreimer, R. Viscidi, M. Pawlita, C. Fakhry, W. M. Koch, et al. 2007. Case-control study of human papillomavirus and oropharyngeal cancer. N. Engl. J. Med. 356:1944-1956.
29. Weinberger, P. M., Z. Yu, B. G. Haffty, D. Kowalski, M. Harigopal, J. Brandsma, et al. 2006. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J. Clin. Oncol. 24:736-747.
30. Fakhry, C., W. H. Westra, S. Li, A. Cmelak, J. A. Ridge, H. Pinto, et al. 2008. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J. Natl. Cancer Inst. 100:261-269.
31. Kirnbauer, R., F. Booy, N. Cheng, D. Lowy, and J. Schiller 1992. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. 89:12180-12184.
32. Lehtinen, M., J. Paavonen, C. M. Wheeler, U. Jaisamrarn, S. M. Garland, X. Castellsagué, et al. 2012. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 13:89-99.
33. Muñoz, N., S. K. Kjaer, K. Sigurdsson, O.-E. Iversen, M. Hernandez-Avila, C. M. Wheeler, et al. 2010. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J. Natl. Cancer Inst. 102:325-339.
34. Giuliano, A. R., J. M. Palefsky, S. Goldstone, E. D. Moreira, M. E. Penny, C. Aranda, et al. 2011. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N. Engl. J. Med. 364:401-411.
35. Palefsky, J. M., A. R. Giuliano, S. Goldstone, E. D. Moreira, C. Aranda, H. Jessen, et al. 2011. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N. Engl. J. Med. 365:1576-1585.
36. Herrero, R., W. Quint, A. Hildesheim, P. Gonzalez, L. Struijk, H. A. Katki, et al. 2013. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One 8:e68329.
37. de Villiers, E. M., C. Fauquet, T. R. Broker, H. U. Bernard, and H. zur Hausen 2004. Classification of papillomaviruses. Virology 324:17-27.
38. Vidal, L., and M. L. Gillison 2008. Human papillomavirus in HNSCC: recognition of a distinct disease type. Hematol. Oncol. Clin. North Am. 22:1125-1142.
39. Gillison, M. L., X. Castellsagué, A. Chaturvedi, M. T. Goodman, P. Snijders, M. Tommasino, et al. 2013. Comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix. Int. J. Cancer 134:497-507.
40. Parkin, D. M., and F. Bray 2006. The burden of HPV-related cancers. Vaccine 24:S11-S25.
41. DeGregori, J., and D. G. Johnson 2006. Distinct and overlapping roles for E2F family members in transcription, proliferation and apoptosis. Curr. Mol. Med. 6:739-748.
42. Chellappan, S., V. B. Kraus, B. Kroger, K. Munger, P. M. Howley, W. Phelps, et al. 1992. Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. Proc. Natl. Acad. Sci. 89:4549-4553.
43. Zerfass, K., A. Schulze, D. Spitkovsky, V. Friedman, B. Henglein, and P. Jansen-Dürr 1995. Sequential activation of cyclin E and cyclin A gene expression by human papillomavirus type 16 E7 through sequences necessary for transformation. J. Virol. 69:6389-6399.
44. McLaughlin-Drubin, M. E., D. Park, and K. Munger 2013. Tumor suppressor p16INK4A is necessary for survival of cervical carcinoma cell lines. Proc. Natl. Acad. Sci. 110:16175-16180.
45. Scheffner, M., B. A. Werness, J. M. Huibregtse, A. J. Levine, and P. M. Howley 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136.
46. Rampias, T., C. Sasaki, P. Weinberger, and A. Psyrri 2009. E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J. Natl. Cancer Inst. 101:412-423.
47. Filippova, M., H. Song, J. L. Connolly, T. S. Dermody, and P. J. Duerksen-Hughes 2002. The human papillomavirus 16 E6 protein binds to tumor necrosis factor (TNF) R1 and protects cells from TNF-induced apoptosis. J. Biol. Chem. 277:21730-21739.
48. Garnett, T., and P. Duerksen-Hughes 2006. Modulation of apoptosis by human papillomavirus (HPV) oncoproteins. Arch. Virol. 151:2321-2335.
49. White, A. E., E. M. Livanos, and T. D. Tlsty 1994. Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes Dev. 8:666-677.
50. Duensing, A., N. Spardy, P. Chatterjee, L. Zheng, J. Parry, R. Cuevas, et al. 2009. Centrosome overduplication, chromosomal instability, and human papillomavirus oncoproteins. Environ. Mol. Mutagen. 50:741-747.
51. Patel, D., A. Incassati, N. Wang, and D. J. McCance 2004. Human papillomavirus type 16 E6 and E7 cause polyploidy in human keratinocytes and up-regulation of G2-M-phase proteins. Cancer Res. 64:1299-1306.
52. Finzer, P., A. Aguilar-Lemarroy, and F. Rösl 2002. The role of human papillomavirus oncoproteins E6 and E7 in apoptosis. Cancer Lett. 188:15-24.
53. Duensing, S., and K. Münger 2002. The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res. 62:7075-7082.
54. Kessis, T. D., D. C. Connolly, L. Hedrick, and K. R. Cho 1996. Expression of HPV16 E6 or E7 increases integration of foreign DNA. Oncogene 13:427-431.
55. Moody, C. A., and L. A. Laimins 2009. Human papillomaviruses activate the ATM DNA damage pathway for viral genome amplification upon differentiation. PLoS Pathog. 5:e1000605.
56. Spardy, N., K. Covella, E. Cha, E. E. Hoskins, S. I. Wells, A. Duensing, et al. 2009. Human papillomavirus 16 E7 oncoprotein attenuates DNA damage checkpoint control by increasing the proteolytic turnover of claspin. Cancer Res. 69:7022-7029.
57. Mork, J., A. K. Lie, E. Glattre, S. Clark, G. Hallmans, E. Jellum, et al. 2001. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 344:1125-1131.
58. INK4a TGFβ, and contact inhibition. Cell 97:53-61.
59. Mendelsohn, A. H., C. K. Lai, I. P. Shintaku, D. A. Elashoff, S. M. Dubinett, E. Abemayor, et al. 2010. Histopathologic findings of HPV and p16 positive HNSCC. Laryngoscope 120:1788-1794.
60. Robinson, M., P. Sloan, and R. Shaw 2010. Refining the diagnosis of oropharyngeal squamous cell carcinoma using human papillomavirus testing. Oral Oncol. 46:492-496.
61. Lewis, J. S. Jr, W. L. Thorstad, R. D. Chernock, B. H. Haughey, J. H. Yip, Q. Zhang, et al. 2010. p16 positive oropharyngeal squamous cell carcinoma: an entity with a favorable prognosis regardless of tumor HPV status. Am. J. Surg. Pathol. 34:1088-1096.
62. Hoffmann, M., S. Tribius, E. S. Quabius, H. Henry, S. Pfannenschmidt, C. Burkhardt, et al. 2012. HPV DNA, E6* I-mRNA expression and p16INK4A immunohistochemistry in head and neck cancer-how valid is p16INK4A as surrogate marker? Cancer Lett. 323:88-96.
63. Harris, S. L., L. B. Thorne, and W. T. Seaman 2011. Neil Hayes D., Couch M.E., and Kimple R.J., Association of p16INK4a overexpression with improved outcomes in young patients with squamous cell cancers of the oral tongue. Head Neck 33:1622-1627.
64. Liang, C., C. J. Marsit, M. D. McClean, H. H. Nelson, B. C. Christensen, R. I. Haddad, et al. 2012. Biomarkers of HPV in head and neck squamous cell carcinoma. Cancer Res. 72:5004-5013.
65. Lewis, J. S. Jr. 2012. p16 Immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma. Head Neck Pathol. 6:75-82.
66. Y., T., and M. M. Manos 1990. Detection and typing of genital human papillomaviruses. Pp. 356-367 in Michael A. Innis, David H. Gelfand, John J. Sninsky, Thomas J. White ed. PCR protocols: a guide to methods and applications. Academic Press Inc, San Diego, CA, USA.
67. De Roda Husman, A. M., J. M. Walboomers, van den Brule A. J., C. J. Meijer, and P. J. Snijders 1995. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J. Gen. Virol. 76: 1057-1062.
68. Morris, B. J. 2005. Cervical human papillomavirus screening by PCR: advantages of targeting the E6/E7 region. Clin. Chem. Lab. Med. 43:1171-1177.
69. Noffsinger, A. E., L. Suzuk, Y. Z. Hui, A. A. Gal, and C. M. Fenoglio-Preiser 1995. Differential sensitivities of E6 type-specific and L1 consensus primers in the detection of human papillomavirus in anal carcinoma. Mod. Pathol. 8:509-514.
70. Bernard, H. U., I. E. Calleja-Macias, and S. T. Dunn 2006. Genome variation of human papillomavirus types: phylogenetic and medical implications. Int. J. Cancer 118:1071-1076.
71. Kornegay, J. R., M. Roger, P. O. Davies, A. P. Shepard, N. A. Guerrero, B. Lloveras, et al. 2003. International proficiency study of a consensus L1 PCR assay for the detection and typing of human papillomavirus DNA: evaluation of accuracy and intralaboratory and interlaboratory agreement. J. Clin. Microbiol. 41:1080-1086.
72. Venuti, A., and F. Paolini 2012. HPV detection methods in head and neck cancer. Head Neck Pathol. 6:63-74.
73. Singhi, A. D., and W. H. Westra 2010. Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer 116:2166-2173.
74. Smeets, S. J., A. T. Hesselink, E. J. M. Speel, A. Haesevoets, P. J. Snijders, M. Pawlita, et al. 2007. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int. J. Cancer 121:2465-2472.
75. Thavaraj, S., A. Stokes, E. Guerra, J. Bible, E. Halligan, A. Long, et al. 2011. Evaluation of human papillomavirus testing for squamous cell carcinoma of the tonsil in clinical practice. J. Clin. Pathol. 64:308-312.
76. Rampias, T., C. Sasaki, and A. Psyrri 2013. Molecular mechanisms of HPV induced carcinogenesis in head and neck. Oral Oncol. 50:356-363.
77. Deng, Z., M. Hasegawa, A. Kiyuna, S. Matayoshi, T. Uehara, S. Agena, et al. 2013. Viral load, physical status, and E6/E7 mRNA expression of human papillomavirus in head and neck squamous cell carcinoma. Head Neck 35:800-808.
78. Holzinger, D., M. Schmitt, G. Dyckhoff, A. Benner, M. Pawlita, and F. X. Bosch 2012. Viral RNA patterns and high viral load reliably define oropharynx carcinomas with active HPV16 involvement. Cancer Res. 72:4993-5003.
79. Ukpo, O. C., J. J. Flanagan, X.-J. Ma, Y. Luo, W. L. Thorstad, and J. S. Lewis 2011. High-risk human papillomavirus E6/E7 mRNA detection by a novel in situ hybridization assay strongly correlates with p16 expression and patient outcomes in oropharyngeal squamous cell carcinoma. Am. J. Surg. Pathol. 35:1343-1350.
80. Schache, A. G., T. Liloglou, J. M. Risk, T. M. Jones, X. J. Ma, H. Wang, et al. 2013. Validation of a novel diagnostic standard in HPV-positive oropharyngeal squamous cell carcinoma. Br. J. Cancer 108:1332-1339.
81. Schache, A. G., T. Liloglou, J. M. Risk, A. Filia, T. M. Jones, J. Sheard, et al. 2011. Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity, and prognostic discrimination. Clin. Cancer Res. 17:6262-6271.
82. Castle, P. E., T. Shields, R. Kirnbauer, M. M. Manos, R. D. Burk, A. G. Glass, et al. 2002. Sexual behavior, human papillomavirus type 16 (HPV 16) infection, and HPV 16 seropositivity. Sex. Transm. Dis. 29:182-187.
83. Cameron, J. E., I. V. Snowhite, A. K. Chaturvedi, and M. E. Hagensee 2003. Human papillomavirus-specific antibody status in oral fluids modestly reflects serum status in human immunodeficiency virus-positive individuals. Clin. Diagn. Lab. Immunol. 10:431-438.
84. Anderson, K., J. Wong, G. D'Souza, A. Riemer, J. Lorch, R. Haddad, et al. 2011. Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer. Br. J. Cancer 104:1896-1905.
85. Punyadeera, C., and P. D. Slowey 2013. Saliva as an emerging biofluid for clinical diagnosis and applications of MEMS/NEMS in salivary diagnostics in K. Subramani, W. Ahmed, J. K. Hartsfield Jr., eds. Nanobiomaterials in clinical dentistry, Elsevier, Oxford, UK.
86. Lima, D. P., D. G. Diniz, S. A. S. Moimaz, D. H. Sumida, and A. C. Okamoto 2010. Saliva: reflection of the body. Int. J. Infect. Dis. 14:e184-e188.
87. Pfaffe, T., J. Cooper-White, P. Beyerlein, K. Kostner, and C. Punyadeera 2011. Diagnostic potential of saliva: current state and future applications. Clin. Chem. 57:675-687.
88. Zhang, X., Y. Wan, J. Cooper-White, G. Dimeski, J. Atherton, and C. Punyadeera 2013. Quantification of D-dimer levels in human saliva. Bioanalysis 5:2249-2256.
89. Smith, E. M., J. M. Ritchie, K. F. Summersgill, H. T. Hoffman, D. H. Wang, T. H. Haugen, et al. 2004. Human papillomavirus in oral exfoliated cells and risk of head and neck cancer. J. Natl. Cancer Inst. 96:449-455.
90. Zhao, M., E. Rosenbaum, A. L. Carvalho, W. Koch, W. Jiang, D. Sidransky, et al. 2005. Feasibility of quantitative PCR-based saliva rinse screening of HPV for head and neck cancer. Int. J. Cancer 117:605-610.
91. Chuang, A. Y., T. C. Chuang, S. Chang, S. Zhou, S. Begum, W. H. Westra, et al. 2008. Presence of HPV DNA in convalescent salivary rinses is an adverse prognostic marker in head and neck squamous cell carcinoma. Oral Oncol. 44:915-919.
92. Agrawal, Y., W. M. Koch, W. Xiao, W. H. Westra, A. L. Trivett, D. E. Symer, et al. 2008. Oral human papillomavirus infection before and after treatment for human papillomavirus 16-positive and human papillomavirus 16-negative head and neck squamous cell carcinoma. Clin. Cancer Res. 14:7143-7150.
93. Koslabova, E., E. Hamsikova, M. Salakova, J. Klozar, E. Foltynova, E. Salkova, et al. 2013. Markers of HPV infection and survival in patients with head and neck tumors. Int. J. Cancer 133:1832-1839.
94. Tachezy, R., J. Klozar, L. Rubenstein, E. Smith, M. Saláková, J. Šmahelová, et al. 2009. Demographic and risk factors in patients with head and neck tumors. J. Med. Virol. 81:878-887.
95. Fakhry, C., B. T. Rosenthal, D. P. Clark, and M. L. Gillison 2011. Associations between oral HPV16 infection and cytopathology: evaluation of an oropharyngeal "pap-test equivalent" in high-risk populations. Cancer Prev. Res. 4:1378-1384.
96. Adamopoulou, M., E. Vairaktaris, V. Panis, E. Nkenke, F. W. Neukam, and C. Yapijakis 2008. HPV detection rate in saliva may depend on the immune system efficiency. In Vivo 22:599-602.
97. Nordfors, C., A. Vlastos, J. Du, A. Ährlund-Richter, N. Tertipis, N. Grün, et al. 2014. Human papillomavirus prevalence is high in oral samples of patients with tonsillar and base of tongue cancer. Oral Oncol. 50:491-497.
98. Hammarstedt, L., D. Lindquist, H. Dahlstrand, M. Romanitan, J. Joneberg, N. Creson, et al. 2006. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int. J. Cancer 119:2620-2623.
99. Dahlgren, L., H. M. Dahlstrand, D. Lindquist, A. Högmo, L. Björnestål, J. Lindholm, et al. 2004. Human papillomavirus is more common in base of tongue than in mobile tongue cancer and is a favorable prognostic factor in base of tongue cancer patients. Int. J. Cancer 112:1015-1019.
100. Masterson, L., D. Moualed, Z. W. Liu, J. E. F. Howard, R. C. Dwivedi, J. R. Tysome, et al. 2014. De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials. Eur. J. Cancer 50:2636-2648.